ProCE Banner Activity

MATRix/IELSG43: Phase III Trial of High-Dose Chemotherapy + ASCT vs Nonmyeloablative Chemoimmunotherapy as Consolidation for Primary CNS Lymphoma

Slideset Download
Conference Coverage

Consolidation with high-dose chemotherapy and ASCT reduced risk of disease progression and death compared with conventional chemoimmunotherapy in primary CNS lymphoma.

Released: December 17, 2022

Expiration: December 16, 2023

No longer available for credit.

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

AbbVie

Amgen

AstraZeneca

Epizyme

GSK

Incyte Corporation

Jazz Pharmaceuticals

Karyopharm Therapeutics Inc.

Novartis Pharmaceuticals Corporation

Sanofi

Seagen